A chiral pool approach toward the synthesis of thalidomide metabolites

Heterocycles

Volumn 70, Issue , 2006, Pages 321-334

  Luzzio, Frederick A ^a   Duveau, Damien Y ^a   Figg, William D ^b  

^a UNIVERSITY OF LOUISVILLE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33947615805     PISSN: 03855414     EISSN: None     Source Type: Journal    
DOI: 10.3987/com-06-s(w)28     Document Type: Article

References (30)

1. Submitted in recognition of the career contributions of Professor Steven M. Weinreb to the art and science of synthetic chemistry.
2. Presented in part at the 229th National Meeting of the American Chemical Society. San Diego, CA (March 13, 2005)
3. Folkman J. Nat. Med. 1 (1995) 27
4. Efferth T. Current Drug Targets 7 (2006) 407
5. Wakabayashi T., Kageyama R., Naruse N., Tsukahara N., Funahashi Y., Kitoh K., and Watanabe Y. J. Antibiot. 50 (1997) 671
6. Furness M.S., Robinson T.P., Ehlers T., Hubbard R.B., Arbiser J.L., Goldsmith D.J., and Bowen J.P. Curr. Pharm. Design 11 (2005) 357
7. Sidbury R., Neuschler N., Neuschler E., Sun P., Wang X.Q., Miller R., Tomai M., Puscasiu E., Gugneja S., and Paller A.S. J. Invest. Dermatol. 121 (2003) 1205
8. Ho P.Y., Liang Y.C., Ho Y.S., Chen C.T., and Lee W.S. Int. J. Cancer 111 (2004) 51
9. (g). Okroj M., Kamysz W., Slominska E.M., Mysliwski A., and Bigda J. Anti-Cancer Drugs 16 (2005) 817
10. Franks M.E., Macpherson G.R., and Figg W.D. Lancet 363 (2004) 1802
11. Figg W.D. Clin. Pharm. Thera. 79 (2006) 1
12. Gasparini G., Longo R., Fanelli M., and Teicher B.A. J. Clin. Oncol. 23 (2005) 1295
13. Luzzio F.A., and Figg W.D. Exp. Opin. Ther. Patents 14 (2004) 215
14. Richardson P., Hideshima T., and Anderson K. Ann. Rev. Med. 53 (2002) 629
15. Marriot J.B., Muller G., Stirling D., and Dalgleish A.G. Exp. Opin. Biol. Ther. 1 (2001) 675
16. Raje N., and Anderson K. N. Engl. J. Med. 341 (1999) 1606
17. Hales B.F. Nat. Med. 5 (1999) 489
18. D'Amato R.J., Loughnan M.S., Flynn E., and Folkman J. Proc. Nat Acad. Sci., U.S.A. 91 (1994) 4082
19. Bauer K.S., Dixon S.C., and Figg W.D. Biochem. Pharmacol. 55 (1998) 1827
20. Knoche B., and Blaschke G. Chirality 6 (1994) 221
21. Eriksson T., Bjorkman S., Roth B., Bjork H., and Hoglund P. J. Pharm. Pharmacol. 50 (1998) 1409
22. Meyring M., Muhlbacher J., Messer K., Kastner-Pustnet N., Bringmann G., Mannschreck A., and Blaschke G. Anal. Chem. 74 (2002) 3726
23. Luzzio F.A., Mayorov A.V., and Figg W.D. Tetrahedron Lett. 41 (2000) 2275
24. Luzzio F.A., Thomas E.M., and Figg W.D. Tetrahedron Lett. 41 (2000) 7151
25. Luzzio F.A., Duveau D.Y., Lepper E.R., and Figg W.D. J. Org. Chem. 70 (2005) 10117
26. Teubert U., Zwingenberger K., Wnendt S., and Eger K. Arch. Pharm. Pharm. Med. Chem. 331 (1998) 7
27. The ornithine→aminoglutarimide cyclization route was also used by Takeuchi (See. Takeuchi Y., Shiragami T., Kimura K., Suzuki E., and Shibata N. for the preparation of fluorinated glutarimide analogues of thalidomide. Org. Lett. 1 (1999) 1571
28. Padrón J.M., Kokotos G., Martin T., Markidis T., Gibbons W.A., and Martin V.S. Tetrahedron, Asym. 9 (1998) 3381
29. Luzzio F.A. Tetrahedron 57 (2001) 915
30. Luzzio F.A. In: Weinreb S.M. (Ed). Science of Synthesis, Houben Weyl's Methods of Molecular Transformations: Compounds with Three and Four Carbon Heteroatom Bonds Vol 21 (2005), Georg Thieme Verlag, Stuttgart 301-302